Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report observed alopecia universalis, a complete hair loss condition, in a patient during a clinical trial with the angiotensin receptor-neprilysin inhibitor sacubitril/alisartan, indicating that ARNI therapy might be associated with such cutaneous reactions.

This article describes an increase in the detection of heart failure among young people and discusses the development of the drug Uperio for its treatment and support.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study highlights the limited number of cross-sectoral evaluations of health interventions and suggests that guidance from health technology assessment agencies could enhance evidence and encourage novel investment in population health.

This case report describes a 27-year-old male with autoimmune polyglandular syndrome type 1, characterized by symptoms including fever, dysarthria, dysphagia, oral candidiasis, nail dystrophy, alopecia, hypoparathyroidism, and dilated cardiomyopathy. The study highlights unique bilateral symmetrical brain calcifications and underscores the syndrome’s diverse manifestations.

This case report highlights the diagnosis of Parry Romberg syndrome in a 52-year-old man within a primary care setting, emphasizing the importance of awareness and team discussion among family physicians for rare conditions.

This study reports a case of fatal HHV-6 encephalitis and vasculitis in a previously healthy 49-year-old male, highlighting the occurrence of this condition even in individuals without typical risk factors, such as immunocompromised status.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

This study identified N-acyl arylsulfonamides, particularly N-(Boc-piperidine-4-carbonyl)-benzenesulfonamides, as steroid sulfatase inhibitors with improved cellular potency compared to previous compounds.

This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.

This study found that treatment with cyproterone acetate and estradiol improved emotional well-being and acceptance of being viewed among women with hirsutism, with no significant differences between oral and transdermal estradiol groups.

This study found that a regimen combining cyproterone acetate and testosterone buciclate induced reversible azoospermia in bonnet monkeys, highlighting its potential as an effective male contraceptive.

This study found that participants with HR-positive/HER2-negative advanced or metastatic breast cancer treated with sacituzumab govitecan had better quality of life and longer survival compared to standard chemotherapy recipients.

This study found that cyproterone acetate treatment improved quality of life and reduced anxiety and depressive symptoms in women with skin manifestations of hyperandrogenism.

This study reports experience treating 140 women with hirsutism and other virilism signs using cyproterone acetate and ethinyl estradiol, focusing on those treated for over five months.

This study found that treatment with cyproterone acetate was generally successful for women with virilizing features, showing improved results in younger women and those with adrenal hirsutism, despite some side effects.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

In this study, cetirizine hydrochloride was formulated into niosomal and cubosomal gels, showing potential for off-label use in treating androgenic alopecia due to effective skin permeation and acceptable safety profiles; cubosomal gels exhibited superior permeation compared to niosomal gels.

This study explored the solubility and crystal structure of GI197111X, a 5-alpha reductase inhibitor for androgenetic alopecia, finding its solubility in Capmul MCM suitable for a soft gel dosage form.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

This review discusses the management of adverse events associated with sacituzumab govitecan use in real-world settings and provides no new clinical results; it emphasizes practical strategies for clinicians treating breast cancer patients.